Implantable infusion devices called intrathecal pumps are surgically inserted beneath the patient’s abdominal skin. These can supply medication to the spine via a catheter, a tiny, flexible tube. These intrathecal drug pain pump implants are typically chosen when a patient needs long-term medication and other options are too costly or ineffective. They can provide exact amounts of medication from one or more reservoir combinations without requiring complicated pumping. By controlling the intrathecal pump drug delivery by medical instructions, a medicine can be infused over an extended period and administered at constant or variable rates. The implanted infusion pump’s self-sealing septum allows for external needle injections to replenish the medication reservoir. These pumps are designed to administer powerful medications in the intrathecal region, which enables the delivery of medications in extremely low doses, for the treatment of chronic pain and spasticity. This lessens the negative effects that the medications have.
An intrathecal drug delivery system consists of two parts, a pump, and an intrathecal catheter. The pump serves as the drug reservoir, and it is implanted under the subcutaneous tissue in the abdominal area. Intrathecal drug delivery is predicated on the idea that some medications can provide effective analgesia in situations where systemic administration cannot provide acceptable concentrations or does not require high systemic doses. When compared to systemic administration, intrathecal drug administration requires lower doses, which also results in fewer side effects.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/intrathecal-pumps-market/
Global Intrathecal Pumps Market-Competitive Insights
On January 12, 2022, Flowonix Medical, Inc., received premarket approval from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the Prometra, a programmable infusion pump system to expand the indications for the device for the intrathecal infusion of baclofen in patient populations of 12 years and older.
Some of the Key Players in the Global Intrathecal pumps Market include –
- Tricumed Medizintechnik GmbH
- Teleflex, Inc.
- Flowonix Medical, Inc.
- Medtronic
- Johnson & Johnson Services, Inc. (Codman and Shurtleff)
- Smiths Medical
- Durect Corporation
- Medallion Therapeutics, Inc.
- Abbott
- Baxter International Inc.
Global Intrathecal Pumps Market – Growth drivers
The growth of the Intrathecal Pumps Market is primarily driven by factors such as the increasing prevalence of chronic diseases, the rising demand for targeted drug delivery systems, technological advancements in intrathecal pumps, and the need for accurate medication dosages to reduce pain medication utilization. Additionally, the market growth is supported by factors like the high prevalence of chronic diseases, improved healthcare infrastructure, and the adoption of advanced devices for enhanced medical care in regions like North America and Europe. Pain is a prevalent and clinically significant illness in the aging population. However, the use of intrathecal pumps has led to better results in the treatment of senior patients with pain. Unfortunately, evaluating pain in geriatric patients is problematic, mostly due to the complexity of multiple comorbidities. According to WHO projects that by 2050, there will be 2 billion individuals worldwide who are 60 years of age or older. The demand for intrathecal pumps will continue to rise as the number of the elderly population grows.
Global Intrathecal Pumps Market -Restraints
The American Food and Drug Administration has not yet authorized the use of intrathecal pumps in any manner. The FDA has issued warnings to people and healthcare providers about the negative effects of taking drugs that are not FDA-approved. Additionally, drugs approved for intrathecal use are subject to stricter safety regulations. Risks including incorrect dosage administration, infections, malfunctioning pumps, opioid withdrawal, and other ailments like twitches in the muscles, confusion, fever, nausea, edema, and cardiac or respiratory distress could prevent the intrathecal market from growing.
Intrathecal Pumps Market -Opportunities
Manufacturers of intrathecal pumps have also been seen to develop devices with longer battery lives, which might reduce the amount of further surgical procedures needed in the future to replace failing pumps. Cancer suffering is becoming more common due to the higher oncologic patients’ survival rates. One of the most common symptoms in individuals with metastatic cancer is pain. Analgesia is one of the several pharmacologic therapies that may be used to treat persistent cancer pain. Intrathecal drug delivery, however, provides a different method of administering analgesics. This method has the advantage of improved bioavailability, which helps to lessen adverse effects and speeds up business growth.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/intrathecal-pumps-market/
Global Intrathecal Pumps Market – Geographical Insights
The highest portion of the global intrathecal pump market in 2021 belonged to North America. During the projected time, the area is expected to dominate the industry. Regional market expansion is being driven by a rise in the demand for intrathecal treatments, a high incidence of cancer and chronic pain, and developments in technology. Because the United States has advantageous reimbursement regulations for intrathecal operations, the country is driving growth in the North American market. Europe was the second-largest market in 2021. Favorable regulatory & reimbursement scenarios and approval of intrathecal devices are expected to propel intrathecal pumps market growth in the region. The market in Asia Pacific is projected to grow at a rapid pace during the forecast period. This is ascribed to a growing economy and strengthening insurance policies. Economic growth in developing countries in the region is expected to increase the disposable income of the patient population, which in turn is likely to propel healthcare expenditure.
Intrathecal pumps Market– key development
- On February 19, 2020, Flowonix Medical, Inc. announced the U.S. Food and Drug Administration (FDA) marketing approval for the Prometra II Programmable Pump System for use with intrathecal baclofen. The company introduced the Prometra II 40mL pump in the U.S. in November 2019.
- On December 5, 2019, the FDA classified the recall of Medtronic’s SynchroMed II implantable drug pumps as Class I, the most serious type of recall. The company announced the voluntary recall in October, indicating that it had received complaints about the pumps’ motors stalling permanently.
- On March 11, 2019, In Piramal Critical Care announced the launch of their intrathecal pump product offering MITIGO (Morphine Sulfate Injection, USP – Preservative-free), in the U.S. market.